Overall CABA gets a fundamental rating of 1 out of 10. We evaluated CABA against 525 industry peers in the Biotechnology industry. CABA has a bad profitability rating. Also its financial health evaluation is rather negative. CABA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year CABA has reported negative net income.
In the past year CABA has reported a negative cash flow from operations.
CABA had negative earnings in each of the past 5 years.
CABA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -83.54%, CABA is not doing good in the industry: 69.14% of the companies in the same industry are doing better.
CABA has a Return On Equity (-113.66%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-83.54%
ROE	-113.66%
ROIC	N/A

ROA(3y)-44.86%

ROA(5y)-40.06%

ROE(3y)-51.8%

ROE(5y)-45.02%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CABA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CABA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CABA has more shares outstanding
Compared to 1 year ago, CABA has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -2.21, we must say that CABA is in the distress zone and has some risk of bankruptcy.
CABA has a Altman-Z score (-2.21) which is comparable to the rest of the industry.
CABA has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
CABA's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. CABA outperforms 42.67% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Altman-Z	-2.21

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

CABA has a Current Ratio of 3.60. This indicates that CABA is financially healthy and has no problem in meeting its short term obligations.
CABA has a Current ratio (3.60) which is comparable to the rest of the industry.
CABA has a Quick Ratio of 3.60. This indicates that CABA is financially healthy and has no problem in meeting its short term obligations.
CABA has a Quick ratio of 3.60. This is comparable to the rest of the industry: CABA outperforms 45.52% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.6
Quick Ratio	3.6

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CABA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.67%.

EPS 1Y (TTM)-17.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%29.03%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

CABA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.20% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y6.31%

EPS Next 2Y10.5%

EPS Next 3Y6.91%

EPS Next 5Y13.2%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CABA. In the last year negative earnings were reported.
Also next year CABA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.